SFS Wellness
Start Here

Longevity

Peptides and longevity research: An educational overview of emerging compounds

Person practising yoga outdoors at sunrise

Interest in peptides related to healthy aging, cellular energy, recovery, and metabolic support continues to grow. Many of these compounds are being studied for their potential roles in mitochondrial function, inflammation, tissue repair, cognitive processes, and hormone signaling. At the same time, the quality and volume of human clinical evidence vary widely—from well-studied approved agents and precursors to compounds that remain largely preclinical or early-stage investigational.

This article provides a clear, unbiased summary of what several widely discussed peptides and related molecules are, how they are being researched, and what peer-reviewed evidence currently shows. It is intended to help readers understand the landscape and ask informed questions of licensed healthcare providers.

Important disclaimer: This content is strictly educational. It is not medical advice and does not recommend, promote, or endorse any product or use. Many of the compounds discussed are not FDA-approved for anti-aging, longevity, or wellness indications. Compounded versions have not been reviewed by the FDA for safety, effectiveness, or quality. Always consult a licensed healthcare provider for personalized decisions. Research findings describe laboratory, animal, or limited human data and do not guarantee outcomes in individuals.

Peptides for longevity: Why do they appear in discussions?

Peptides are short chains of amino acids that can act as signaling molecules. In aging research, investigators study certain peptides for effects on:

  • Inflammatory signaling
  • Tissue repair and recovery
  • Hormone pathways (including growth hormone axis)
  • Cognitive and neuroprotective mechanisms
  • Immune regulation

Evidence ranges from robust clinical trials (for some approved or precursor compounds) to primarily preclinical (cell and animal) data for many research peptides.

Featured compounds and current research snapshot

NAD+ and NAD+ Precursors

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism. Levels tend to decline with age in some tissues. Research focuses on precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) that can raise NAD+-related metabolites.

Peer-reviewed human trials show that oral NMN or NR can increase blood or cellular NAD+-related markers and are generally well tolerated in short- to medium-term studies. Effects on functional outcomes (walking speed, sleep quality, metabolic markers) have been mixed or modest in randomized trials. A 2025 review in Nature Metabolism concluded that while target engagement is clear, clinical evidence for broad anti-aging benefits remains limited and tissue-specific data are still sparse. Injected NAD+ itself lacks robust controlled outcome trials for longevity indications.

Glutathione

Glutathione is the body’s primary intracellular antioxidant. It supports detoxification pathways and redox balance. Oral, intravenous, and other forms have been studied for various conditions. Evidence for direct longevity benefits in healthy aging populations is limited; most clinical data relate to specific disease contexts or oxidative stress markers rather than lifespan or broad healthspan endpoints.

Epithalon (Epitalon)

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on pineal gland extracts. Laboratory studies have reported telomerase activation and telomere-related effects in certain cell lines, with some independent replication in 2025. Animal work has explored geroprotective signals. Human data consist mainly of older observational series (often involving related pineal extracts rather than pure synthetic Epitalon) and small clinical series on circadian or melatonin markers. No modern randomized, placebo-controlled human trials demonstrating lifespan extension or comprehensive anti-aging outcomes have been published. Reviews note gaps in independent toxicology and long-term safety data.

MOTS-c

A mitochondria-derived peptide encoded in the mitochondrial genome. Preclinical studies (notably in mice) have shown effects on insulin sensitivity, metabolic homeostasis, and exercise capacity via AMPK-related pathways. Human data are largely observational (circulating levels correlating with metabolic status and age). A Phase 2a randomized trial examining insulin sensitivity in adults with prediabetes and overweight/obesity began recruiting in 2026 (ClinicalTrials.gov NCT07505745); results are not yet available. No completed human efficacy trials for longevity endpoints exist as of mid-2026.

KPV

A tripeptide fragment with reported anti-inflammatory and antimicrobial properties in laboratory models. Research has focused on gut barrier function, skin, and inflammatory signaling. Human clinical evidence remains limited; most data are preclinical.

Semax

A synthetic peptide derived from an ACTH fragment, studied primarily in Russian and Eastern European literature for cognitive and neuroprotective effects. Some small clinical studies have examined memory, attention, and recovery contexts. High-quality, large-scale Western randomized trials are scarce.

AOD-9604

A modified fragment of human growth hormone studied for effects on fat metabolism. Early human trials (including a larger Phase 2b study) did not meet primary weight-loss endpoints when combined with diet and exercise. Safety observations were generally favorable relative to placebo, but development for obesity was discontinued. Evidence for broader metabolic or longevity benefits is limited.

SS-31 (Elamipretide)

A mitochondria-targeting peptide that binds cardiolipin and has been studied for mitochondrial function. Clinical trials have examined primary mitochondrial myopathy, Barth syndrome, and other conditions. Some studies showed improvements in mitochondrial energetics or functional measures; larger trials have produced mixed primary endpoint results. It is the most clinically advanced among the mitochondria-focused peptides listed here, though not approved for general anti-aging use.

TB-500 (Thymosin Beta-4 Fragment)

Investigated in preclinical models for tissue repair, cell migration, and recovery. Human clinical data for longevity or general recovery indications remain limited.

CJC-1295 / Ipamorelin

Growth hormone secretagogues studied for their ability to stimulate endogenous growth hormone release. Research has examined body composition, recovery, and related parameters under medical supervision. Clinical use, when it occurs, is typically prescription-based and individualized; long-term longevity outcome data are limited.

Sermorelin

A growth hormone-releasing hormone analog previously approved for diagnostic or pediatric growth hormone deficiency contexts. It has been studied for stimulating endogenous GH release. Use in adult “healthy aging” settings is off-label or compounded in some jurisdictions and requires medical oversight. Evidence for broad anti-aging benefits is modest.

Thymosin Alpha-1

A synthetic version of a naturally occurring thymic peptide with immunomodulatory properties. It has been studied and, in some countries, used for certain infectious and immune-related conditions. Clinical trials (including a recent large sepsis trial) have produced mixed results on hard outcomes. Research continues on immune aging (immunosenescence) and vaccine response in older adults.

How to interpret the evidence

  • Stronger evidence exists for NAD+ precursors (biochemical target engagement) and for certain approved or advanced clinical candidates such as elamipretide in specific mitochondrial diseases.
  • Most of the research peptides listed above rely primarily on preclinical (cell and animal) data or small/early human studies. Claims of lifespan extension or broad anti-aging effects in humans are not supported by rigorous controlled trials.
  • Regulatory status matters: FDA-approved products have undergone formal review. Compounded or research-only peptides have not received the same evaluation for safety, quality, or effectiveness in longevity contexts.
  • Individual responses, long-term safety, optimal dosing, and real-world outcomes remain areas of active investigation.

Practical considerations for informed readers

When reviewing information about these compounds:

  • Look for primary peer-reviewed publications rather than secondary summaries or marketing materials.
  • Distinguish FDA-approved drugs, investigational agents in formal trials, and compounded or research chemicals.
  • Ask about the quality of evidence (randomized controlled trials vs. observational or preclinical data).
  • Consider that lifestyle factors (nutrition, exercise, sleep, stress management) remain the foundation of healthy aging research.

Peer-reviewed and regulatory references

Interested in learning more about peptides for longevity?

Learn about approaches that may help support cellular energy production, metabolic health, recovery, and healthy aging.

Want to explore products? Visit the SFS Wellness Shop to explore products related to longevity, energy and vitality.

Educational content only, not medical advice. Clinical eligibility and treatment decisions are handled by licensed professionals. Results vary and are not guaranteed.

Chat is temporarily unavailable

Please contact SFS Wellness directly while we finish preparing the secure chat experience. Do not send medical, prescription, payment, or emergency information.

For medical questions, including dosing or treatment protocols, please contact Patient Support at +1 (888) 471-9962.